Brain-computer interface startups worldwide are competing to bring neural devices to market. Chinese companies appear to be leading the pack.
Brain-computer interfaces (BCIs) promise to fundamentally reshape human-technology interaction, enabling direct neural control of devices. The sector has attracted significant investment globally, with startups in the US, Europe, and Asia pursuing regulatory approval for commercial deployment.
China's BCI ecosystem is advancing rapidly, with multiple companies developing implantable and non-invasive neural interfaces. The nation's streamlined regulatory processes and substantial government support are accelerating timelines for device testing and approval.
Key applications under development include mobility assistance for paralyzed patients, cognitive enhancement, and direct neural communication. Technical hurdles remain—including signal interpretation accuracy, biocompatibility, and long-term device stability.
International competition is intensifying as companies race toward regulatory milestones. Success in early clinical trials could unlock significant commercial markets, particularly in rehabilitation and assistive technology sectors.
Moonshot AI, the Chinese company behind the Kimi chatbot, is targeting a $30 billion valuation in its latest funding round—more than six times its late-2025 worth.
While venture-backed e-bike companies filed for bankruptcy, bootstrapped Lectric expanded aggressively, launching three new brands in six months. The company believes the U.S. market has room for more competition.
Seed-stage startup funding in Japan plummeted 42% year-over-year in 2025, dropping to 19.9 billion yen ($124 million)—the lowest level in a decade. The decline coincides with the Tokyo Stock Exchange's efforts to reduce small company listings.
Jeff Bezos is funding Flourish, a neuroscience startup seeking to identify the brain's fundamental algorithmic principles. The company has raised $500 million and carries a $2.5 billion valuation.